Related Experiment Videos
Acute urinary morbidity following I-125 prostate brachytherapy
Toshio Ohashi1, Atsunori Yorozu, Kazuhito Toya
1Department of Radiology, Tokyo Medical Center, National Hospital Organization, 2-5-1 Higashigaoka, Tokyo 152-8902, Japan. tohashi@ntmc.hosp.go.jp
International Journal of Clinical Oncology
|September 2, 2005
Summary
Acute urinary morbidity, including frequency and retention, is common but manageable after iodine-125 (I-125) prostate brachytherapy. This study assessed these side effects in patients undergoing I-125 treatment.
Area of Science:
- Urology
- Oncology
- Radiation Therapy
Background:
- Iodine-125 (I-125) prostate brachytherapy is increasingly utilized in Japan since its 2003 approval.
- Assessing early urinary side effects is crucial for patient management.
Purpose of the Study:
- To evaluate acute urinary morbidity within six months following I-125 prostate brachytherapy.
Main Methods:
- 130 patients with localized prostate cancer received I-125 brachytherapy (monotherapy or combined with external-beam radiotherapy).
- Urinary morbidity was assessed using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v3.0.
Main Results:
- 85.4% of patients experienced urinary symptoms like frequency and retention.
- Urinary frequency (73.1%) and retention (66.9%) were most prevalent, with no significant difference between monotherapy and combined therapy.
- 4.6% of patients required catheterization for urinary obstruction, with a median onset of 1.5 days.
Conclusions:
- Acute urinary morbidity, particularly frequency and retention, is common after I-125 prostate brachytherapy.
- These side effects are generally considered acceptable in the context of this treatment modality.